Infectious diseases & clinical microbiology最新文献

{"title":"Is There a Role for Dark Field Microscopy in the Diagnosis of Lyme Disease?A Narrative Review.","authors":"Uğur Önal, Fatma Saraç-Pektaş, İmran Sağlık","doi":"10.36519/idcm.2023.291","DOIUrl":"https://doi.org/10.36519/idcm.2023.291","url":null,"abstract":"<p><p>The diagnosis of Lyme disease is becoming more common in Turkey. Nonetheless, some physicians are not aware of the diagnostic principles that should be followed when faced with a suspected patient and could use tests that are not recommended, such as darkfield microscopy. Dark field microscopy is a diagnostic technique to visualize the spirochetes that cause Lyme disease; however, it is not recommended for the diagnosis of Lyme disease. One of the main limitations of dark field microscopy is its low sensitivity. Another limitation is its high false-positivity rate, as other microorganisms and cellular debris can be mistaken for spirochetes, leading to a misdiagnosis thatmay result in unnecessary treatment. Therefore, this study aimed to review the literature on the role of dark field microscopy as a diagnostic method for Lyme disease and inform physicians about recommended approaches in line with the recommendations of national or international guidelines. An electronic search of Pubmed, Scopus, and Web of Science was performed using the following medical subject headings (MeSH) search terms: Lyme borreliosis, Lyme disease, <i>Borrelia burgdorferi</i>, diagnosis, and microscopy. With this narrative review, we aimed to inform physicians better and improve patient care for patients with suspected Lyme disease.</p>","PeriodicalId":519881,"journal":{"name":"Infectious diseases & clinical microbiology","volume":"5 4","pages":"281-286"},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10986710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140854693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Serum Krebs von den Lungen-6 (KL-6) Levels and Disease Severity in Patients Hospitalized with COVID-19.","authors":"Oğuz Evlice, Murat Bektaş, Fatih Kar, Feride Marim, İlknur Kaya, Kerem Yörükoğlu, Öznur Ak","doi":"10.36519/idcm.2023.260","DOIUrl":"https://doi.org/10.36519/idcm.2023.260","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to evaluate Krebs von den Lungen-6 (KL-6) as a possible biomarker in determining disease severity in patients with moderate and severe COVID-19.</p><p><strong>Materials and methods: </strong>This cross-sectional study included moderate or severe COVID-19 patients; critically ill patients who were followed up in the intensive care unit were not included. KL-6 level and routine laboratory test measurements were performed on the first day of admission. The patients were also categorized according to their hyperinflammatory state.</p><p><strong>Results: </strong>The study included 92 patients, 56 (61%) women. The National Institutes of Health (NIH) score was 2 in 52.2% of the patients and 3 in 47.8%. KL-6 levels did not significantly differ in disease severity (NIH score 2 vs. 3; <i>p</i>=0.15). Median KL-6 values were 52.7 (29.1) in patients with <2 COVID-19 hyperinflammatory syndrome score (cHIS) and 61.7 (32.2) in patients with cHIS ≥ 2 (<i>p</i>= 0.077). KL-6 values tended to be higher among the patients with lower lymphocyte counts, but the difference was not statistically significant (<1000 mm³/L <i>p</i>=0.006 and higher cHIS scores ≥2 <i>p</i>=0.07). KL-6 values were also higher in the patients with diabetes mellitus compared to the remaining patients (<i>p</i> =0.036).</p><p><strong>Conclusion: </strong>There was no significant association between the serum KL-6 measured at admission and the severity of COVID-19.</p>","PeriodicalId":519881,"journal":{"name":"Infectious diseases & clinical microbiology","volume":"5 4","pages":"292-299"},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10986708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140874375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a Nanoplate-Based Digital PCR Test Method for Quantitative Detection of Human Adenovirus DNA.","authors":"Yağmur Eylül Doğantürk, Aylin Dağ-Güzel, Mert Ahmet Kuşkucu","doi":"10.36519/idcm.2023.255","DOIUrl":"https://doi.org/10.36519/idcm.2023.255","url":null,"abstract":"<p><strong>Objective: </strong>Digital polymerase chain reaction (dPCR) assay is an advanced PCR technique that allows for the simultaneous detection and absolute quantification of diverse pathogens.Commercially validated kits available for detecting all subtypes of human adenovirus (HAdV) are limited. This study aimed to demonstrate the development of an in-house nanoplate-based dPCR assay with high sensitivity, even at low copy numbers.</p><p><strong>Materials and methods: </strong>In this methodological study, the standardized HAdV DNA was prepared by amplifying the specific hexon gene region with real-time PCR and purifying the HAdV DNA using magnetic beads from HAdV-positive extractions. Dilutions were tested in triplicate during three independent runs to determine the dynamic range, the limit of detection (LoD), the limit of quantification (LoQ), precision, and reproducibility. The primer and probe sequences used in the study were selected based on a literature review to ensure the detection of all HAdV serotypes in a single run. The selected primers were verified using the US National Center for Biotechnology Information (NBCI) nBLAST tools, and the target sequence was determined using the BioEdit software. The DNA concentration of the stock solution was measured using a Qubit fluorometer. The estimated copy number of the stock solution per milliliter was calculated based on the length of the amplified base sequence and fluorometer measurement.</p><p><strong>Results: </strong>The dynamic range of the test was determined to be from 770.4 to 0.9476 cp/μl, with the LoD and LoQ values both being 0.9476 cp/μl. The coefficient of determination (r ²) value of the test was 0.9986.</p><p><strong>Conclusion: </strong>The results demonstrated that the dPCR method could be an ideal tool for the diagnosis and absolute quantification of human adenoviruses, especially in low copy numbers. In order to determine the reproducibility of the test and validate the method for field use, it needs to be developed and adapted in various laboratories and supported by clinical studies.</p>","PeriodicalId":519881,"journal":{"name":"Infectious diseases & clinical microbiology","volume":"5 4","pages":"353-366"},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10986707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140864339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New Treatment Options in Chronic Hepatitis B: How Close Are We to Cure?","authors":"Pınar Korkmaz, Ali Asan, Faruk Karakeçili, Süda Tekin, Neşe Demirtürk","doi":"10.36519/idcm.2023.265","DOIUrl":"https://doi.org/10.36519/idcm.2023.265","url":null,"abstract":"<p><p>Hepatitis B virus (HBV) infection is the leading cause of chronic liver disease worldwide. HBV-infected patients are at a lifetime risk of developing liver cirrhosis and hepatocellular carcinoma (HCC). Today, pegylated interferon (Peg-IFN) and nucleos(t)ide analogs (NAs) are used in the treatment of patients with chronic hepatitis B (CHB). Both treatment options have limitations. Despite effective viral suppression, NAs have little effect on covalently closed circular DNA (cccDNA), the stable episomal form of the HBV genome in hepatocytes. Therefore, the cure rate with NAs is low, and long-term treatment is required. Although the cure rate is better with Peg-IFN, it is difficult to tolerate due to drug side effects. Therefore, new treatment options are needed in the treatment of HBV infection. We can group new treatments under two headings: those that interfere with the viral life cycle and spread and those that modulate the immune response. Clinical studies show that combinations of treatments that directly target the viral life cycle and treatments that regulate the host immune system will be among the important treatment strategies in the future. As new direct-acting antiviral (DAA) and immunomodulatory therapies continue to emerge and evolve, functional cures in HBV treatment may be an achievable goal.</p>","PeriodicalId":519881,"journal":{"name":"Infectious diseases & clinical microbiology","volume":"5 4","pages":"267-280"},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10986727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140875102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Hospitalized Patients with Community-Acquired Influenza-Like Illness During Two Influenza Seasons.","authors":"Özge Özgen-Top, Pınar Aysert-Yıldız, Hasan Selçuk Özger, Özlem Güzel-Tunçcan","doi":"10.36519/idcm.2023.285","DOIUrl":"https://doi.org/10.36519/idcm.2023.285","url":null,"abstract":"<p><strong>Objective: </strong>Influenza is among the most important respiratory infections affecting all age groups and can lead to hospitalizations. We aimed to determine the frequency of influenza infections among acute admissions with influenza-like illness (ILI) and evaluate the demographic, clinical findings, and outcomes of patients with influenza.</p><p><strong>Methods: </strong>This prospective, active surveillance study was conducted in a university hospital between 2015 and 2017. Patients hospitalized for at least 24 hours in the selected units with community-acquired ILI were screened according to certain influenza-predicting ICD-10 codes. Nasopharyngeal and pharyngeal swab samples were taken from patients who were eligible for the study. Patients tested for influenza with real-time polymerase chain reaction. Univariate and multivariate analyses were performed for data.</p><p><strong>Results: </strong>Among 440 patients screened according to influenza-related ICD-10 codes, 112 were included. Influenza positivity was detected in 37 of the 112 patients. Clinical findings were similar between influenza positive and negative groups and also between influenza subtypes, excluding sore throat, which was more common in the H1N1 group. Alanine transaminase (ALT), aspartate transaminase (AST), and creatine kinase (CK) elevations were found to be significantly higher in the influenza-positive group. When influenza-positive patients with and without pneumonia were compared, the rate of vaccination in the same season was higher in patients without pneumonia than in patients with pneumonia (38.8% and 10.5%, respectively; <i>p</i>=0.04).</p><p><strong>Conclusion: </strong>Integrating molecular tests detecting both influenza and other respiratory viruses into influenza surveillance programs can increase the efficacy and quality of these programs. The elevation of AST, ALT, and CK in influenza cases can be considered in distinguishing influenza from other ILI cases. Vaccination in the same season can reduce the risk of pneumonia in influenza-positive patients.</p>","PeriodicalId":519881,"journal":{"name":"Infectious diseases & clinical microbiology","volume":"5 4","pages":"323-331"},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10986686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140868007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Procalcitonin Levels in Identifying Bacterial Infections in Children with and without COVID-19.","authors":"Grace Fisler, Timothy Brandt, G Amin Ostovar, Matthew D Taylor, Sareen Shah","doi":"10.36519/idcm.2023.300","DOIUrl":"https://doi.org/10.36519/idcm.2023.300","url":null,"abstract":"<p><strong>Objective: </strong>Elevated procalcitonin levels have been associated with bacterial infection in children. Observational studies reported high procalcitonin values in COVID-19. Data on bacterial coinfections in pediatric COVID-19 is sparse; small studies suggest a low coinfection rate. In this study, we aimed to quantify the positive predictive value (PPV) of procalcitonin in identifying bacterial infection in children with and without COVID-19.</p><p><strong>Materials and methods: </strong>A retrospective chart review was performed for 215 children <21 years admitted to our tertiary children's hospital between February 1, 2013, and July 15, 2020, who had procalcitonin levels measured within 48 hours of admission. Confirmed bacterial infection was defined as positive blood, urine, or cerebrospinal fluid (CSF) culture, positive endotracheal culture with evidence of leukocytosis on Gram stain, or pneumonia by chest radiograph. Suspected bacterial infection was defined as confirmed bacterial infection or administration of antibiotics for >48 hours.</p><p><strong>Results: </strong>Of the 215 patients, 73 were admitted for COVID-19 (66% multisystem inflammatory syndrome in children [MIS-C], 34% acute COVID-19). The PPV of an elevated procalcitonin level >1.0 ng/mL in identifying suspected bacterial infections for those with MIS-C was 6.3% (95% CI=0-15), in acute COVID-19 was 29% (95% CI=0-62%), and in the non-COVID-19 cohort was 75% (95% CI=62-88%). For identification of confirmed bacterial infection, PPV of an elevated procalcitonin level was 0% in MIS-C, 14% (95% CI=0-40%) in acute COVID-19, and 55% (95% CI=40-69%) in the non-COVID-19 cohort.</p><p><strong>Conclusion: </strong>We found a low PPV of elevated procalcitonin level above 1 ng/mL in identifying either culture-confirmed or presumed bacterial infection in children hospitalized with COVID-19-related illness.</p>","PeriodicalId":519881,"journal":{"name":"Infectious diseases & clinical microbiology","volume":"5 4","pages":"287-291"},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10986730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140874169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-Dose Crossover Comparative Bioavailability Study of Two Different Posaconazole 100 mg Gastro-Resistant Tablets Under Fasted and Fed Conditions in Healthy Volunteers.","authors":"Nilden Dayan, Elif Oğralı, Cihan Kirişçioğlu, Udaya Kumar Dude, Recep Erşahin","doi":"10.36519/idcm.2023.277","DOIUrl":"https://doi.org/10.36519/idcm.2023.277","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to compare the bioavailability of two different gastro-resistant oral tablet formulations of posaconazole under fasted and fed conditions and to evaluate a potential food effect on the bioavailability of each formulation.</p><p><strong>Materials and methods: </strong>Healthy volunteers randomly assigned to receive a test product (Posagil^® 100 mg gastro-resistant tablet) or reference product (Noxafil^® 100 mg gastro-resistant tablet) were included in this single-center, randomized, four-period (days 1, 15, 29 and 43), four-sequence crossover comparative bioavailability study. Data on posaconazole plasma concentrations and related pharmacokinetic profile (the maximum observed plasma concentration [C_max] from time 0 to the time of last observed quantifiable plasma concentration [AUC_0-T] and from time zero to infinity [AUC_0-∞]) were recorded to evaluate efficacy of the test product in relation to the reference product under both fasted and fed conditions, based on bioequivalence (T-fasted vs. R-fasted and T-fed vs. R-fed) and food effect (T-fasted vs. T-fed and R-fasted vs. R-fed) assessments. Safety was evaluated through assessment of adverse events (AEs), standard laboratory evaluations, and vital signs.</p><p><strong>Results: </strong>The bioequivalence criteria were met under fed conditions (T-fed vs. R-fed: geometric LSMean ratios of C_max, AUC_0-T, and AUC_0-∞ of posaconazole were 97.41%, 97.45%, and 97.08%, respectively; all within the range of 80% to 125%) but not under fasted conditions. There was a food effect on the reference product (R-fed vs. R-fasted: geometric LSMean ratios of C_max, AUC_0-T, and AUC_0-∞ of posaconazole were 145.32%, 138.84%, and 138.46%, respectively) but not on the test product. No safety concerns were identified.</p><p><strong>Conclusions: </strong>Our findings suggest that the pharmacokinetic profile of Posagil^® is similar to the pharmacokinetic profile of Noxafil^®. The generic Posagil^® seems to have similarly high bioavailability under fed and fasted conditions, offering a higher posaconazole exposure than the original Noxafil^® in the fasted state. Hence, Posagil^® may be considered a value-added generic product that offers adequate posaconazole exposure under fasted state and fed state, regardless of the concomitant high-fat meal intake.</p>","PeriodicalId":519881,"journal":{"name":"Infectious diseases & clinical microbiology","volume":"5 4","pages":"341-352"},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10986696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knidos Medical School and its Reflections on Modern Medicine.","authors":"Önder Ergönül","doi":"10.36519/idcm.2023.313","DOIUrl":"https://doi.org/10.36519/idcm.2023.313","url":null,"abstract":"","PeriodicalId":519881,"journal":{"name":"Infectious diseases & clinical microbiology","volume":"5 4","pages":"380-382"},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10986719/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140857859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brucellar Epididymo-Orchitis in a Brucellosis Hyperendemic Region in Türkiye.","authors":"Hatun Öztürk-Çerik, Latif Mustafa Özbek, Betül Altıntaş-Öner, İlkay Bozkurt","doi":"10.36519/idcm.2023.253","DOIUrl":"https://doi.org/10.36519/idcm.2023.253","url":null,"abstract":"<p><strong>Objective: </strong>Brucellosis is one of the most prevalent zoonoses worldwide and is endemic in Türkiye. It is a multisystemic infection that can affect various organ systems. Epididymo-orchitis is the most common form of genitourinary involvement. This study aimed to evaluate the incidence, clinical characteristics, laboratory values, and treatment outcomes of brucellar epididymo-orchitis (BEO) in the East Anatolian region, where brucellosis is hyperendemic.</p><p><strong>Materials and methods: </strong>This study was conducted between January 1, 2018, and April 30, 2019. All male patients diagnosed with brucellosis at the infectious disease clinic were evaluated for epididymo-orchitis according to clinical findings (testicular pain, swelling, erythema). In addition, to identify BEO patients, all epididymo-orchitis cases admitted to the urology outpatient clinic according to the study protocol were referred to the infectious diseases clinic for <i>Brucella</i> infection. Patients were enrolled prospectively, and data were analyzed retrospectively.</p><p><strong>Results: </strong><i>Brucella</i> infection was diagnosed in 326 patients during the study period, of whom 208 (63.8%) were male. Brucellar epididymo-orchitis was diagnosed in 18 patients at the end of sixteen months. The incidence of epididymo-orchitis in patients with <i>Brucella</i> infection was 8.7%. The mean age of the patients was 36.9±11.5 years. The majority of patients had occupational animal contact (83.3%) and consumption of fresh cheese made from raw milk (55.5%). Acute brucellosis was diagnosed in 17 (94.4%) patients; all patients presented with scrotal pain and swelling. Unilateral epididymo-orchitis was observed in 16 (88.8%) patients. Most patients (88.3%) applied to outpatient clinics other than infectious diseases, especially the urology clinic (77.7%).Double or triple combined treatments with aminoglycoside/doxycycline/rifampicin were given to the patients. Hydrocelectomy was performed in three patients, orchiectomy in one patient, and relapse was seen in one patient.</p><p><strong>Conclusion: </strong><i>Brucella</i> infection should be considered in patients presenting with epididymo-orchitis in endemic regions. Awareness of brucellosis by urologists will ensure that the disease is diagnosed without complications.</p>","PeriodicalId":519881,"journal":{"name":"Infectious diseases & clinical microbiology","volume":"5 4","pages":"367-375"},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10986701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140856932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bibliometric Analysis of Human Metapneumovirus Studies.","authors":"Işıl Deniz Alıravcı, Taylan Çelik, Semiha Çelik-Ekinci, Aziz Ahmad Hamidi","doi":"10.36519/idcm.2023.250","DOIUrl":"https://doi.org/10.36519/idcm.2023.250","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to estimate research productivity and general characteristics of research in different regions of the world in the field of human metapneumovirus (hMPV).</p><p><strong>Materials and methods: </strong>We used the Web of Science (WoS) electronic database to retrieve articles on \"human metapneumovirus,\" published up to March 31, 2023. Parameters such as research productivity, the total number of publications, average citation counts of all articles, research productivity by top publishing countries and affiliated organizations, links between countries/organizations, and top keywords were assessed.</p><p><strong>Results: </strong>We found 826 articles in the WoS database. The first article on hMPV was published in 2002, and 2008 was the year that the most articles on hMPV were published, with 70 articles. The articles were cited 26,797 times (14,498 times without self-citations) and 32.25 times on average per article. Hirsch (H)-index was 80. The year 2008 also had the highest number of citations, with more than 1800. The United States was the most productive country, producing 295 documents (35.714%), one-third of all publications in this field worldwide. Canada (6.5%) and Japan (6.5%) followed the United States regarding total hMPV publications worldwide. The leading funding agencies for hMPV research were from the United States, Europe, China, and Japan.</p><p><strong>Conclusion: </strong>Our findings imply that developed countries should assist developing countries in enhancing their research infrastructures.</p>","PeriodicalId":519881,"journal":{"name":"Infectious diseases & clinical microbiology","volume":"5 4","pages":"311-322"},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10986691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140854692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}